Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Oncolytics Biotech (ONCY) is back on investors' radars after ...

Ladies and gentlemen, thank you for standing by. Welcome to the Cardiff Oncology ASCO Data Presentation Conference Call. [Operator Instructions] Please be advised that today's conference is being ...

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

“Made in China” is becoming “made by China”—all over the world. Faced with higher Western tariffs and weak demand at home, many Chinese factories are moving abroad, making everything from appliances ...

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...

Florida-based AP governance firm selected as an RFP-stage contender, reinforcing its leadership in SAP vendor and customer master data compliance, modernization, and enterprise AP controls. PORT ST.

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...

China treats data as a factor of production, not a privacy right or corporate asset, and is building economic infrastructure around it: regulated data exchanges, 30+ new standards expected in 2026, ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

China’s April 2025 export restrictions on heavy rare earths and permanent magnets triggered rapid disruptions across allied defense and industrial supply chains, exposing the fragility of a system ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...